凝血酶市场规模、份额及成长分析（依产品、剂型、最终用户及地区划分）－2026-2033年产业预测

预计到 2024 年，全球凝血酶市场规模将达到 6.6296 亿美元，到 2025 年将达到 6.9942 亿美元，到 2033 年将达到 10.734 亿美元，预测期（2026-2033 年）的复合年增长率为 5.5%。

由于凝血酶在止血和血液凝固中发挥重要作用，尤其是在外科手术和创伤护理中，全球凝血酶市场正经历显着增长。心血管和整形外科手术数量的增加以及人口老化是推动市场需求的关键因素。重组凝血酶等创新技术提高了产品的安全性和有效性，同时解决了与动物性产品相关的担忧。生物技术和製药领域（例如再生医学和创伤治疗）的不断扩展的应用也支持市场发展。北美凭藉其先进的医疗保健基础设施和有利的报销政策引领市场，其次是欧洲。亚太地区的新兴市场，特别是中国和印度，儘管面临高昂的製造成本和监管障碍等挑战，预计仍将实现显着成长。

全球凝血酶市场驱动因素

全球对凝血酶产品的需求主要受外科手术数量不断增加的驱动，而外科手术数量的增加主要是由于人口老化以及心血管疾病和癌症等非传染性疾病的增加。在每年全球数百万例外科手术中，凝血酶在约65%的心血管手术和55%的整形外科手术中发挥关键作用，作为主要的局部止血剂来控制出血。此外，微创手术的日益普及进一步增加了对有效止血解决方案（如凝血酶）的需求，这些解决方案能够快速有效地控制出血，从而确保手术成功。

限制全球凝血酶市场的因素

全球凝血酶市场面临许多限制因素，尤其是重组凝血酶的高成本。这项先进的生物技术生产的产品价格昂贵，限制了其供应和使用，尤其是在发展中地区经济拮据的医疗机构。由于这些机构倾向于选择价格较低的止血剂，高昂的生产成本成为市场渗透和广泛应用的障碍。因此，许多医疗机构面临的经济压力限制了凝血酶产品在最需要的地方有效利用。

全球凝血酶市场趋势

随着人们对更安全、更纯净的传统牛凝血酶替代品的需求日益增长，全球凝血酶市场正经历着向重组凝血酶产品的重大转变。这项转变的驱动力主要来自外科手术领域，尤其是医疗保健领域对可靠止血剂需求的不断增长，因为微创手术技术需要精准有效的止血。此外，生物技术的进步和病人安全意识的提高也促进了重组产品的广泛应用，使其逐渐成为医疗专业人员和医疗机构的首选。因此，这一趋势有可能重塑凝血酶市场的竞争格局。

目录

介绍

• 调查目标
• 调查范围
• 定义

调查方法

• 资讯收集
• 二手资料和一手资料方法
• 市场规模预测
• 市场假设与限制

执行摘要

• 全球市场展望
• 供需趋势分析
• 细分市场机会分析

市场动态与展望

• 市场规模
• 市场动态
  • 驱动因素和机会
  • 限制与挑战
• 波特分析

关键市场考察

• 关键成功因素
• 竞争程度
• 关键投资机会
• 市场生态系统
• 市场吸引力指数（2025）
• PESTEL 分析
• 总体经济指标
• 价值链分析
• 定价分析
• 案例研究
• 顾客购买行为分析

全球凝血酶市场规模（依产品类型及复合年增长率划分）（2026-2033 年）

• 牛凝血酶
• 人类凝血酶
• 重组凝血酶

全球凝血酶市场规模（依剂型划分）及复合年增长率（2026-2033 年）

• 粉末
• 溶液剂型

全球凝血酶市场规模（依最终用户划分）及复合年增长率（2026-2033 年）

• 医院
• 诊断中心
• 研究所

全球凝血酶市场规模及复合年增长率（2026-2033）

• 北美洲
  • 美国
  • 加拿大
• 欧洲
  • 德国
  • 西班牙
  • 法国
  • 英国
  • 义大利
  • 其他欧洲地区
• 亚太地区
  • 中国
  • 印度
  • 日本
  • 韩国
  • 亚太其他地区
• 拉丁美洲
  • 巴西
  • 其他拉丁美洲地区
• 中东和非洲
  • 海湾合作委员会国家
  • 南非
  • 其他中东和非洲地区

竞争资讯

• 前五大公司对比
• 主要企业的市场定位（2025 年）
• 主要市场参与者所采取的策略
• 近期市场趋势
• 公司市占率分析（2025 年）
• 主要企业公司简介
  • 公司详情
  • 产品系列分析
  • 依业务板块进行公司股票分析
  • 2023-2025年营收年比比较

主要企业简介

• Pfizer Inc.
• Johnson & Johnson Services Inc.
• Baxter International Inc.
• Shanghai RAAS Blood Products Co. Ltd.
• GE Healthcare
• Bayer AG
• CSL Behring
• Grifols
• Hualan Biological Engineering
• Haematologic Technologies Inc.
• Octapharma AG
• Omrix Biopharmaceuticals Ltd.
• Japan Blood Products Organization
• Mallinckrodt Pharmaceuticals
• Mochida Pharmaceutical Co. Ltd.

结论与建议

Global Thrombin Market size was valued at USD 662.96 Million in 2024 and is poised to grow from USD 699.42 Million in 2025 to USD 1073.4 Million by 2033, growing at a CAGR of 5.5% during the forecast period (2026-2033).

The global thrombin market is experiencing significant growth, driven by its essential role in hemostasis and blood coagulation, particularly within surgical and trauma settings. Increasing surgical procedures in areas like cardiovascular and orthopedic surgery, along with a rising elderly population, are key factors propelling market demand. Innovations, including recombinant thrombin, have improved product safety and efficacy while addressing concerns associated with animal-derived products. The market is further supported by expanding applications in biotechnology and pharmaceuticals, such as regenerative medicine and wound healing. North America leads the market due to its advanced healthcare infrastructure and favorable reimbursement policies, while Europe follows closely. Emerging markets in Asia-Pacific, particularly China and India, are poised for substantial growth, despite challenges from high manufacturing costs and regulatory hurdles.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Thrombin market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Thrombin Market Segments Analysis

Global Thrombin Market is segmented by Product, Dosage Form, End-User and region. Based on Product, the market is segmented into Bovine Thrombin, Human Thrombin and Recombinant Thrombin. Based on Dosage Form, the market is segmented into Powder Form and Solution Form. Based on End-User, the market is segmented into Hospitals, Diagnostic Centers and Research Institutions. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Thrombin Market

The global demand for thrombin products is significantly driven by the rising number of surgical procedures, largely attributed to an ageing population and the increasing prevalence of non-communicable diseases such as cardiovascular disorders and cancer. With millions of surgical interventions conducted worldwide annually, thrombin plays a critical role in approximately 65% of cardiovascular surgeries and 55% of orthopedic operations, serving as a key local hemostatic agent to control bleeding. Additionally, the trend towards minimally invasive surgeries emphasizes the necessity for effective hemostatic solutions like thrombin, which ensures successful surgical outcomes by facilitating timely and skilled bleeding management.

Restraints in the Global Thrombin Market

The global thrombin market faces significant constraints due to the high costs associated with producing thrombin, particularly recombinant thrombin. This advanced biotechnology results in expensive products, which can limit their availability and usage, especially in economically challenged healthcare facilities in developing regions. As these facilities often opt for more affordable hemostatic alternatives, the high production costs create a barrier to market penetration and widespread application. Consequently, the financial constraints faced by many healthcare providers hinder the potential for thrombin products to be utilized effectively in settings where they are most needed.

Market Trends of the Global Thrombin Market

The global thrombin market is witnessing a significant shift towards recombinant thrombin products, reflecting an increasing preference for safer and purer alternatives to traditional bovine-source thrombin. This shift is being propelled by the rising demand for reliable hemostatic agents in surgical settings, particularly as the healthcare sector embraces minimally invasive techniques that require precise and effective hemostasis. Additionally, advancements in biotechnology and heightened awareness regarding patient safety are contributing to the growing adoption of recombinant options, positioning them as the preferred choice among healthcare professionals and institutions. Consequently, this trend is poised to reshape the competitive landscape of the thrombin market.

Table of Contents

Introduction

• Objectives of the Study
• Scope of the Report
• Definitions

Research Methodology

• Information Procurement
• Secondary & Primary Data Methods
• Market Size Estimation
• Market Assumptions & Limitations

Executive Summary

• Global Market Outlook
• Supply & Demand Trend Analysis
• Segmental Opportunity Analysis

Market Dynamics & Outlook

• Market Overview
• Market Size
• Market Dynamics
  • Drivers & Opportunities
  • Restraints & Challenges
• Porters Analysis
  • Competitive rivalry
  • Threat of substitute
  • Bargaining power of buyers
  • Threat of new entrants
  • Bargaining power of suppliers

Key Market Insights

• Key Success Factors
• Degree of Competition
• Top Investment Pockets
• Market Ecosystem
• Market Attractiveness Index, 2025
• PESTEL Analysis
• Macro-Economic Indicators
• Value Chain Analysis
• Pricing Analysis
• Case Studies
• Customer Buying Behavior Analysis

Global Thrombin Market Size by Product & CAGR (2026-2033)

• Market Overview
• Bovine Thrombin
• Human Thrombin
• Recombinant Thrombin

Global Thrombin Market Size by Dosage Form & CAGR (2026-2033)

• Market Overview
• Powder Form
• Solution Form

Global Thrombin Market Size by End-User & CAGR (2026-2033)

• Market Overview
• Hospitals
• Diagnostic Centers
• Research Institutions

Global Thrombin Market Size & CAGR (2026-2033)

• North America (Product, Dosage Form, End-User)
  • US
  • Canada
• Europe (Product, Dosage Form, End-User)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Product, Dosage Form, End-User)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Product, Dosage Form, End-User)
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Product, Dosage Form, End-User)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2025
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2025
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2023-2025)

Key Company Profiles

• Pfizer Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Johnson & Johnson Services Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Baxter International Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Shanghai RAAS Blood Products Co. Ltd.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• GE Healthcare
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bayer AG
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• CSL Behring
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Grifols
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Hualan Biological Engineering
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Haematologic Technologies Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Octapharma AG
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Omrix Biopharmaceuticals Ltd.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Japan Blood Products Organization
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Mallinckrodt Pharmaceuticals
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Mochida Pharmaceutical Co. Ltd.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations